Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen.
about
Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBDUse of thiopurines in inflammatory bowel diseaseHow I treat my inflammatory bowel disease-patients with thiopurines?Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.Treatment of gout in a renal transplant patient leading to severe thrombocytopenia.Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial.Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.Allopurinol use in pregnancy in three women with inflammatory bowel disease: safety and outcomes: a case series.Allopurinol reduces antigen-specific and polyclonal activation of human T cells.Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.Optimizing thiopurine therapy in inflammatory bowel disease.Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.The role of thiopurine metabolite monitoring in inflammatory bowel disease.Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital.Histological remission of autoimmune hepatitis after the addition of allopurinol and azathioprine dose reduction.Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction.Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.Clinically relevant drug-drug interactions in oncology.Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.Observations on the use of allopurinol in combination with azathioprine or mercaptopurine.Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD.
P2860
Q24616161-323C2C1C-21D1-40E2-AE1E-031AA5C81EDCQ26824662-772E6043-6CB0-469C-A559-94AC6E70AA97Q28076561-E9FE9399-46DD-4239-8D0A-BB48E8D84138Q33393356-5A253749-8210-4AEB-B6DA-FD841E1C5429Q33416558-556258E6-52E1-442B-88A3-95D25937C54AQ34065513-A254CABD-E79D-4614-B97A-26B2D4402CCBQ34446588-39DC8890-838E-45F3-96CD-CA0E2B60E9F9Q35068800-948347E9-D6FE-45F2-9880-D697755A507DQ36250232-C2EDF42A-3A1B-42CB-B69A-8F64B30DD65AQ37094598-3DC29BD3-FAEF-4871-A825-EEC21BA62F14Q37800458-A8571A5A-5E57-4FFA-8D69-9228CECD4A54Q38179509-6B2A11C7-497E-4A89-89DF-85872BEE1BC7Q38195146-A8CCFA03-E503-4AFD-87ED-6E7532E5C81BQ38200692-197E1164-33A0-4B1C-BC13-6110A11948A6Q38253469-C470A211-B90E-434E-A94E-87C4B88ABF3BQ38417177-C0140B1A-C37D-49BB-9896-7793AB3B507BQ38608975-4B5DE095-9F01-4FAE-9FBD-1C33AE977738Q39035303-5078CD78-A08D-430D-A47F-0AF1FE83F8B6Q40230618-D3E62950-0371-4B4C-92DC-1F9BACD88D31Q41985008-83A0BD09-63D4-4BEB-A27B-F51838D5E46EQ42284655-9B4B1DAB-6C81-4968-88C2-5C58E2AAAC54Q42788962-177C38F4-66A1-4D6B-AA03-6625F6FEAC6AQ46283911-52053CE0-D011-456F-A1A6-48FF7A77F53FQ46561246-D46DED76-DA40-4DA4-AD07-F595EEAD791CQ46818066-2428765A-DCFB-4646-9578-1CC401D2A617Q49292225-FA531CEB-9B0A-44E1-AF7A-5D4C77516949
P2860
Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@ast
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@en
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@nl
type
label
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@ast
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@en
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@nl
prefLabel
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@ast
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@en
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@nl
P2093
P1433
P1476
Low-dose allopurinol plus azat ...... vel immunosuppressive regimen.
@en
P2093
H A Simmonds
J S Cameron
P356
10.1016/0140-6736(93)91287-V
P407
P577
1993-07-01T00:00:00Z